The sensitivity of tumors to cyclophosphamide ( CPA ) and other anticancer prodrugs can be substantially enhanced by transduction of tumors with a prodrug -activating mammalian cytochrome P450 ( CYP ) enzyme in combination with the flavoenzyme P450 reductase. This gene therapy strategy provides for intratumoral prodrug activation, but is also associated with a high level of hepatic prodrug activation, which reduces the extent of intratumoral prodrug activation and contributes to systemic drug toxicity. To address this issue, five P450 inhibitors were tested for their ability to block liver CYP2C -catalyzed CPA activation selectively, i.e., without inhibiting the corresponding intratumoral activation of CPA catalyzed by a transduced CYP2B enzyme. In vitro studies revealed that the P450 inhibitors 1 -aminobenzotriazole and DDEP were preferentially inhibitory toward CYP2C -dependent liver microsomal CPA activation, whereas the P450 inhibitor SKF -525A inhibited CYP2C -and CYP2B -dependent CPA activation without P450 form selectivity. By contrast, the P450 inhibitors chloramphenicol and metyrapone preferentially inhibited CYP2B -dependent CPA activation. Rat pharmacokinetic studies confirmed the inhibitory action of these compounds in vivo, with up to a 4 -fold decrease in C max and a 7 -fold increase in apparent half -life of the activated CPA metabolite, 4 -hydroxy -CPA, seen in the case of 1 -aminobenzotriazole. Although the rate of hepatic CPA activation could thus be decreased substantially by P450 inhibitor treatment, the net extent of hepatic CPA activation was only modestly decreased, as judged by plasma area -under -the -curve values for 4 -hydroxy -CPA. Moreover, P450 inhibitor treatment did not decrease CPA's host toxicity and did not enhance the tumor growth delay response to CPA in rats bearing CYP2B1 -transduced gliosarcomas. These findings are discussed in the context of P450 -based gene therapy strategies and ongoing efforts to enhance anticancer drug activity by increasing the exposure of P450 -expressing tumors to the P450 -activated prodrug CPA. Cancer Gene Therapy ( 2001 ) 8, 450 ± 458
S
everal approaches have been developed to enhance the efficacy and reduce the systematic toxicities associated with many commonly used anticancer drugs. One approach, applicable to anticancer prodrugs, involves the chemosensitization of tumor cells by introduction of genes encoding prodrug -activating enzymes not normally expressed in tumor tissue. 1 This strategy has been exemplified for several prodrugs, including the antimetabolite prodrugs ganciclovir 2,3 and 5-fluorocytosine, 4, 5 and the alkylating agent prodrugs cyclophosphamide (CPA ) and ifosfamide. 6 ± 8 CPA and ifosfamide are widely used cancer chemotherapeutic agents that require cytochrome P450 ± catalyzed metabolism to yield a 4 -hydroxy metabolite, which in turn undergoes spontaneous chemical degradation to form the direct acting alkylating agents phosphoramide mustard ( CPA ) and isophosphoramide mustard (ifosfamide), respectively. 9, 10 The P450 enzymes that activate CPA and ifosfamide in liver tissue 11, 12 are generally expressed in human tumors at very low levels. To effect P450 -based cancer gene therapy, a CPA or ifosfamide -activating P450 gene, such as rat
CYP2B1
6,7,13 or human CYP2B6, 14 can be introduced into tumor cells using a variety of vectors, including novel viral vectors 15, 16 or cellular vectors. 17, 18 Cotransduction of P450 reductase, a rate -limiting component of P450 -dependent drug metabolism, further enhances the rate of intratumoral CPA activation, as demonstrated in cell culture and in various preclinical animal tumor models. Thus, 9L gliosarcoma cells transfected with either CYP2B6 /P450 reductase or CYB2B1 /P450 reductase are much more susceptible to CPA cytotoxicity than wild -type 9L tumor cells or 9L tumor cells transduced with a CYP2B gene alone, both in cell culture and in subcutaneous (s.c. ) tumors growing in vivo in mice and rats. 14, 19 This overall strategy can be extended to other established anticancer drugs subject to P450 activation, 20 as well as to bioreductive drugs 21 and other novel anticancer agents. 22, 23 An important advantage of this P450-based gene therapy strategy is its ability to generate active metabolites that can readily diffuse from the site of their generation into adjacent cells and thereby exert bystander cytotoxicity 24 on tumor cells not transduced with P450/ P450 reductase. 8, 21 A substantial antitumor effect can thus be achieved even under conditions where only a small portion of tumor cells is transduced with the prodrug -activating P450 gene.
CPA and several other anticancer prodrugs are primarily metabolized in the liver, where drug -metabolizing cyto-chrome P450 enzymes are expressed at high levels. This dominance of hepatic compared to tumor cell ± catalyzed CPA activation is likely to be maintained, even in the context of P450 gene therapy, owing to the fact that the levels of cytochrome P450 that can be transduced into tumors using current technologies are very low compared to those naturally found in liver. Activated CPA metabolites formed in the liver circulate widely and contribute in a major way to the toxicity of CPA toward sensitive host tissues, such as hematopoietic cells in bone marrow. These systemic toxicities might be minimized in patients undergoing P450 -based cancer gene therapy if a way could be found to decrease the extent to which CPA is activated in liver compared to tumor. One approach to this goal involves the selective suppression of the expression of P450 reductase in liver by administration of methimazole, a clinically useful antithyroid drug. 25 Methimazole treatment of rats suppresses P450 reductase activity in the liver by $80%, with little or no effect on tumor cell P450 reductase levels. Accordingly, methimazole decreases the systemic toxicities of CPA, as judged by body weight, survival rate, and the occurrence of hematuria, while enhancing the anticancer effect of CPA. 25 A second possible approach involves localized administration of CPA at the site of the tumor 26 in a manner that may enhance intratumoral P450 metabolism at the expense of liver P450 metabolism. 27 A third approach involves the use of chemical inhibitors of liver-expressed P450 enzymes to selectively suppress the activation of CPA in liver. This latter approach is investigated in the present study, where we characterize the effect of several P450 inhibitors on the activation of CPA by liver and tumor-expressed P450 enzymes, both in vitro and using in vivo pharmacokinetics and P450 gene therapy ± based antitumor models.
MATERIALS AND METHODS

Chemicals
CPA, 1-aminobenzotriazole ( ABT ), chloramphenicol, metyrapone, methimazole (MMI ), and NADPH were purchased from Sigma Chemical (St. Louis, MO ). 4 -Hydroperoxy -CPA was a gift from Dr. Ulf Niemeyer ( ASTA Pharma, Frankfurt, Germany ). 3,5 -Dicarbethoxy-2, 6 -dimethyl -4 -ethyl -1,4-dihydropyridine (DDEP) was kindly provided by Dr. M. A. Correia ( University of California at San Francisco, CA ). SKF -525A was a gift from Smith -Kline Beecham Pharmaceuticals (King of Prussia, PA ). All other chemicals were analytical grade or better and were purchased from Sigma or Aldrich Chemical ( Milwaukee, WI ).
CPA 4 -hydroxylation assay
CPA 4-hydroxylase activity was determined as described elsewhere. 28 ± 30 Incubations were carried out in a total volume of 100 L containing 50 mM potassium phosphate buffer (pH 7.4 ), 1 mM NADPH, 100 g rat liver microsomes, and 0.25 mM CPA. Where indicated, the P450 inhibitors SKF -525A and metyrapone were directly added to reaction mixtures to give the final concentrations indicated in the figure legends. The mechanism -based P450 inhibitors ABT, DDEP, and chloramphenicol were preincubated with rat liver microsomes at a range of concentrations for 15 minutes at 378C. Substrate ( CPA ) and a fresh aliquot of NADPH were then added. Reactions were incubated at 378C for 20 minutes and stopped by the sequential addition of 40 L of ice -cold 5.5% ZnSO 4 , 40 L of saturated barium hydroxide, and 40 L of 0.01 M HCl. Samples were then spun at 14,000 rpm for 20 minutes. The supernatant (80 L) was transferred to a new tube, where the CPA metabolite acrolein was derivatized with 3-aminophenol and analyzed by HPLC with fluorescence detection. 30 Calibration curves for acrolein were generated in parallel using chemically activated CPA ( 4-hydroperoxy -CPA ) incubated with bovine serum albumin under the same assay conditions.
In vivo P450 inhibition study
Male Fischer 344 rats ( 8± 9 weeks old, 175 ±200 g) were purchased from Taconic (Germantown, NY ) and maintained in the Laboratory for Animal Care Facility at Boston University, with food and water ad libitum. Fifteen rats were divided into five inhibitor treatment groups: (a ) intraperitoneal ( i.p. ) injection of propylene glycol vehicle alone; i.p. injection with vehicle together with: (b ) 100 mg / kg ABT; ( c) 300 mg /kg chloramphenicol; ( d) 80 mg /kg SKF -525A; or (e ) 125 mg /kg DDEP. Two hours later, the rats were killed and the livers were removed and quickly frozen in liquid nitrogen. Microsomes were prepared from these livers by ultracentrifugation. Microsomal protein concentrations were determined by the Bradford method using bovine serum albumin as standard. Microsomal CPA 4 -hydroxylase activities were determined as described above.
Pharmacokinetics
Male Fischer 344 rats, 175± 200 g, were used for the pharmacokinetic studies. Rats were catheterized via the right jugular vein to allow for pharmacokinetic sampling. 31 After recovery from surgery for 3 days, P450 inhibitors were administered by i.p. injection at the same doses used in the in vivo P450 inhibition study (see above ), unless indicated otherwise, and an intravenous bolus of CPA (100 mg /kg ) was given 2 hours later. In some cases, the rats were treated with MMI via the drinking water at a concentration of 0.025% ( wt /vol ) for 10 days before carrying out the pharmacokinetic studies as described. 25 Blood samples ( 500 L at each time point ) were withdrawn via the catheter at various time points ( 0, 4, 10, 25, 40, 60, 90, 120, 180, and 270 minutes ) after CPA injection. The t= 0 minutes time point was taken immediately before the injection of CPA and was used to establish the background plasma level of 4 -hydroxy -CPA. This sample was also used for preparation of a calibration curve after spiking with standard amounts of 4 -hydroperoxy -CPA. At each time point, the volume of blood withdrawn was replaced with an equal volume of 0.9% saline. Blood samples containing CPA metabolites were mixed with 2 U heparin and stabilized with 5 mM semicarbazide. Blood samples were centrifuged at 14,000 rpm for 4 minutes and 100 L of plasma was placed in a clean tube and immediately frozen at À 808C until analysis.
The concentration of plasma 4 -hydroxy -CPA was determined as described elsewhere. 31 
Tumor growth delay assay
Male Fischer 344 rats, 175 ±200 g, were divided into six drug and inhibitor treatment groups at the doses described below (five to six rats per group ): ( a) Control; (b ) CPA alone ( 75 mg / kg); (c ) ABT + CPA; (d ) MMI + ABT +CPA; ( e) SKF -525A + CPA; and ( f) MMI + SKF -525A + CPA. 9L tumor cells (2Â10 6 ) were injected s.c.: 9L /2B1 -Red cells on the left thigh and 9L /wt cells on the right thigh of each rat. 9L /2B1 -Red cells were obtained by transduction of 9L / wt cells with pBabe-based retroviral vectors containing cDNAs encoding rat P450 form CYP2B1 and rat P450 reductase. 25 When the tumors reached 100 mm 2 in size, the rats were given a single dose of the indicated P450 inhibitors by i.p. injection, followed 2 hours later by treatment with CPA ( 75 mg /kg body wt, i.p. ) or 0.9% saline as a control. This dose of CPA was lower than the maximal inhibitory antitumor dose, and was chosen to facilitate detection of improved antitumor effects in the P450 inhibitor ±treated animals. The dose of SKF -525A (60 mg / kg, i.p. ) was somewhat lower than that used in the pharmacokinetic study ( 80 mg /kg ) to minimize toxicity seen with the SKF -525A ( 80 mg /kg) + CPA (75 mg /kg ) combination. The dose of ABT used in the tumor growth delay assay was also decreased to 50 mg /kg, i.p. to avoid potential toxicities that could arise over the several-week period of the tumor growth delay study. No major difference in 4 -OH -CPA pharmacokinetics was seen at 50 vs. 100 mg /kg ABT ( see Table 1 , below ). Tumor sizes were measured twice a week using vernier calipers, and are expressed as tumor areas ( lengthÂwidth ). 32 Tumor volumes were calculated from the measured tumor areas as outlined in Ref. 32 using the formula: volume = /6(LW ) 3 / 2 . Tumor growth delay data were analyzed as described previously 25 except that tumor volumes were used for the calculations in place of tumor areas. Tumor doubling time was defined as the time in days required for the tumor volume to double from the time of first drug treatment. Tumor growth delay values were then calculated as the difference in tumor doubling time between the drug -treated and control groups. Specific growth delay values were calculated as (T 2 À T 1 ))/T 1 , where T 1 and T 2 are times in days required for the control and the drugtreated tumors, respectively, to double in volume. The specific growth delay parameter provides an estimate of the number of doubling times by which tumor growth is delayed by drug treatment, and enables comparisons of therapeutic responses between tumors that differ in their growth rates. 33 
Data analysis
Data were analyzed using Microsoft Excel and GraphPad Prism ( GraphPad Software, San Diego, CA ). Pharmacokinetic parameters [area under the curve (AUC ), CL, C max , t 1 / 2 ] were calculated using WinNonlin software (Scientific Consulting ). Statistical analyses were performed using the unpaired two -tailed t test and Microsoft Excel software.
RESULTS
P450-based gene therapy using the anticancer prodrug CPA has been exemplified using rat P450 gene CYP2B1 or the corresponding human P450 gene, CYP2B6. The major P450 enzyme catalysts of CPA activation in untreated (i.e., uninduced ) adult male rat liver, CYP2C6 and CYP2C11, 34 exhibit substrate specificities and inhibitor sensitivities distinct from CYP2B1. This suggests that selective inhibitors of liver P450 -catalyzed CPA activation can be identified. To assay for such P450 form -selective inhibitors, we carried out incubations in vitro using liver microsomes from uninduced rats as a model for endogenous liver P450 metabolism. The potency of each P450 inhibitor was also evaluated in incubations with liver microsomes isolated from phenobarbital ( PB )-treated rats ( where CYP2B1 is the major catalyst of CPA activation 28, 34 ), which were taken to represent the in situ activation of CPA in tumor cells transduced with the CYP2B1 gene. Figure 1 compares the effects of five P450 inhibitors on CPA 4 -hydroxylation catalyzed by liver microsomes isolated from uninduced and PB -induced rats. The P450 inhibitor DDEP exhibited little inhibitory activity toward CPA 4 -hydroxylation in PB -induced liver microsomes at a concentration of 50 M, but showed $90% inhibition toward CPA 4-hydroxylase activity in uninduced liver microsomes under the same conditions (panel A ). A lower degree of selectivity was seen with ABT, which at 50 M exhibited 60% inhibition of CPA activation catalyzed by uninduced liver microsomes compared to 25% inhibition in PB -induced microsomes ( panel B ). SKF -525A, a more general P450 inhibitor, strongly inhibited CPA activation catalyzed by both untreated and PB -induced liver microsomes, with no selectivity apparent ( panel C ). By contrast, chloramphenicol and metyrapone preferentially inhibited AUC, area under curve; t 1 / 2 , half -life; C max , peak plasma concentration. Student's t test value: *P < .05, **P < .01, ***P < .001 for comparisons with the Control group. Data for the control and MMI groups are those presented in Ref. 25 Data shown are mean SD values. Data for ABT + MMI are based on the 100 mg / kg ABT dose. Data for SKF -525A alone were available for only one rat and are not shown.
yND À t 1 / 2 values could not be reliably determined from the pharmacokinetic profiles. CPA activation catalyzed by PB -induced liver microsomes ( panels D, E ). These latter findings are consistent with the known selectivity of chloramphenicol and metyrapone for inhibition of CYP2B1. 35, 36 To further confirm in vivo the effects of these inhibitors on CPA 4 -hydroxylation seen in vitro, four of the P450 inhibitors were administered to uninduced adult rats. Two hours later, livers were excised and CPA 4-hydroxylation was assayed in isolated liver microsomes (Fig 2 ) . DDEP ( 125 mg /kg, i.p. ) 37 showed only 30% inhibition when administered in vivo, in contrast to its much more extensive inhibition in vitro (cf., Fig  1 ) . This lower-than -anticipated inhibitory effect of DDEP could relate to the difficulties that we encountered in effectively solubilizing DDEP for in vivo delivery using either propylene glycol or corn oil as vehicle. Consequently, DDEP was not used in further studies. In vivo treatment with ABT (100 mg /kg, i.p. ) 38 effected $55 ±60% inhibition of hepatic microsomal CPA activation, whereas SKF -525A treatment (80 mg / kg, i.p. ) 39 effected $30% inhibition at the dose used. This latter value may understate the full extent of inhibition by SKF -525A in vivo because SKF -525A bound to microsomal liver P450 enzymes may be partially lost during the course of microsome preparation. Chloramphenicol ( 300 mg / kg, i.p. ) 35 was the most effective inhibitor in vivo under the conditions tested, effecting a 75% decrease in uninduced liver microsomal CPA 4 -hydroxylase activity (Fig 2) .
The effects of these P450 inhibitors on hepatic CPA activation were then investigated in a rat pharmacokinetic Figure 1 . In vitro inhibition of CPA 4 -hydroxylase activities in liver microsomes isolated from untreated rats and from PB -induced rats. Liver microsomes were preincubated for 15 minutes at 378C with ABT, DDEP, or chloramphenicol in the presence of NADPH at the concentrations indicated. CPA 4 -hydroxylase activity was then determined as described in Materials and Methods. The inhibitory activity of SKF -525A was assayed directly without a preincubation step. Activities are expressed as percentage of control ( minus inhibitor ) activity, which corresponded to 0.17 and 1.8 nmol 4 -OH -CPA formed / minutes / mg for untreated and PB -induced rat liver microsomes, respectively. Each point re-presents the mean of duplicate determinations. Figure 2 . In vivo inhibition of CPA 4 -hydroxylase activity assayed in liver microsomes isolated from rats treated with DDEP, ABT, SKF -525A, or chloramphenicol (CAP). Fischer 344 rats ( male, 175 ± 200 g ) were given a single injection of 125 mg / kg DDEP, 100 mg / kg ABT, 80 mg / kg SKF -525A, or 300 mg / kg chloramphenicol. The rats were killed 2 hours later and the livers then removed and frozen in liquid nitrogen immediately. Liver microsomes were prepared and CPA 4 -hydroxylase activity was assayed as described in Materials and Methods. Data shown represent mean SD activities for n = 3 rats.
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HUANG AND WAXMAN: LIVER P450 INHIBITORS AND P450 GENE THERAPY study ( Fig 3A and Table 1 ). AUC and C max values for the activated CPA metabolite, 4 -OH -CPA, were decreased by ABT treatment, both at 50 and at 100 mg / kg, i.p., whereas the half -life of 4 -OH -CPA was increased up to > 7 -fold. These findings evidence the inhibition of hepatic CPA activation in ABT-pretreated rats compared to controls. Coadministration of ABT with the antithyroid drug MMI, which decreases the expression of liver P450 reductase by $75% and thereby inhibits hepatic P450 metabolism, 25 further decreased the AUC and C max values for 4 -OH -CPA ( Table 1 and Fig 3B ) . SKF -525A (80 mg /kg, i.p. ), either alone or in combination with MMI, also inhibited the initial rate hepatic activation of CPA significantly, although in this case it did not decrease the overall extent of 4 -OH -CPA formation, as judged by AUC values. Similar to SKF -525A, chloramphenicol treatment ( 300 mg /kg, i.p. ) did not alter the AUC of 4-OH -CPA, but did increase the t 1 / 2 and decrease the C max of 4-OH -CPA. Co -administration of MMI with chloramphenicol decreased the t 1 / 2 of 4-OH -CPA, and this effect was associated with a substantial decrease in AUC.
Given the inhibitory effects of ABT on CPA activation revealed by the pharmacokinetic studies ( Table 1 ) , we next examined the effects of this P450 inhibitor, either alone or in combination with MMI, on CPA antitumor activity using an in vivo tumor growth delay assay. The effects of SKF -525A Figure 3 . Plasma 4 -OH -CPA concentration ± time profiles in rats treated with P450 inhibitors with or without MMI treatment. Rats were untreated or were treated with MMI via the drinking water for 7 days, at which point the animals ceased to grow. Jugular vein catheterization followed by a 4 -OH -CPA pharmacokinetic analysis was then carried out to monitor the effects of ABT ( 100 mg / kg ), SKF -525A ( 80 mg / kg ), and chloramphenicol ( 300 mg / kg ) on CPA activation. A single dose of CPA ( 100 mg / kg, i.v. bolus ) was given to the rats 2 hours after P450 inhibitor treatment, as indicated. Plasma 4 -OH -CPA concentrations were determined at each time point control. The control rat data ( no P450 inhibitor and no MMI treatment ) shown in panel A are regraphed in panel B. Pharmacokinetic parameters obtained from these data are presented in Table 1 . or SKF -525A +MMI were also examined. Rats were inoculated with 9L gliosarcoma cells by s.c. injection. 9L tumor cells transduced with both P450 2B1 and P450 reductase (9L /2B1 -Red cells) were implanted on the left thigh, and control 9L tumor cells (9L / wt, devoid of endogenous P450 2B1 ) were implanted on the right thigh of each rat. The antitumor activity of CPA against tumors that express P450 2B1 + P450 reductase is a reflection of intratumoral CPA activation plus hepatic CPA activation, whereas the activity seen in 9L /wt tumors reflects hepatic activation of the prodrug alone. Tumors were grown to $100 mm 2 , at which time a single dose of ABT (50 mg / kg, i.p. ), SKF -525A (60 mg /kg, i.p. ) or saline was administered to the rats. Two hours later, a single dose of CPA ( 75 mg /kg, i.p. ) was injected. The results are shown in Figures 4 and 5 , and the tumor growth delay effects summarized in Table 2. CPA treatment delayed the growth of 9L /wt tumor by 2.8 days, as compared with a 13.1-day growth delay for 9L / 2B1 -Red tumors. This confirms our earlier finding that the introduction of a CPA -activating CYP2B gene in combination with P450 reductase significantly enhances CPA's antitumor activity. 19 ABT and SKF -525A treatment did not, however, further improve the antitumor activity of CPA treatment in 9L /2B1 -Red or in 9L / wt tumors ( Table 2 ) . With the addition of MMI, CPA antitumor activity improved to a small extent, as seen for 9L /2B1 -Red tumors by comparing the MMI + SKF -525A +CPA combination to treatment with SKF -525A + CPA alone ( Fig 5A ) . This effect of the SKF -525+ MMI combination did not reach statistical significance during the first tumor volume doubling (Table 2 ) , but became more pronounced during the later stages of tumor growth (Fig 5A ) . Figure 5 . Antitumor effects of CPA in rats treated with SKF -525A and MMI. Tumor implantation, animal treatments, and data presentation are similar to those described in Figure 4 , except that the P450 inhibitor was SKF -525A ( 60 mg / kg, i.p. ). Examination of the tumor-bearing rats revealed a significant CPA -induced decrease in body weight during the first 6 days, followed by a resumption of weight gain at a rate equal to that of untreated controls ( Fig 6A ) . This CPA -induced host toxicity was not ameliorated in the rats treated with ABT or SKF -525A. CPA -induced body weight loss was abolished by MMI pretreatment, as seen earlier, 25 but no further effect of P450 inhibitor treatment could be detected ( Fig 6B ) .
DISCUSSION
Five P450 inhibitors were investigated for their potential utility in enhancing the therapeutic efficacy of cancer gene therapy using P450 enzymes in combination with the P450-activated prodrug CPA. 8 The primary goal of these studies was to determine whether the systemic toxicities of CPA could be reduced and /or the therapeutic efficacy of CPA enhanced by using P450 form -selective inhibitors, which might be used to inhibit prodrug activation catalyzed by endogenous liver P450 enzymes without inhibiting the corresponding activation of CPA in tumor cells transduced with a CPA -activating CYP2B enzyme. Previous studies have established that CYP2C6 and CYP2C11 are the major P450 enzymes responsible for activation of CPA in uninduced rat liver, whereas CYP3A enzymes are major catalysts of CPA inactivation via an alternative pathway involving CPA Ndechloroethylation. 28, 34 Of the five inhibitors examined, ABT and DDEP were anticipated to be the best candidates for a liver-selective P450 inhibitor, insofar as ABT is a suicide substrate that is particularly active against P450s of the CYP2C and CYP3A subfamilies, 38 whereas DDEP preferentially induces prosthetic heme destruction of rat hepatic P450 enzymes CYP2C11, CYP2C6, CYP3A1, and CYP3A2. 37 A third compound tested, SKF -525A, is a more general P450 inhibitor and does not display substantial P450 form specificity. 40 The inhibitor chloramphenicol inactivates both CYP2C 35, 41 and CYP2B enzymes in rats, 35, 42 whereas a fifth inhibitor, metyrapone, has been characterized as a preferential inhibitor of CYP2B enzymes. 36 Accordingly, these latter two compounds were not expected to effect selective inhibition of liver CPA activation.
In vitro studies of the effects of these P450 inhibitors on CPA activation revealed that DDEP could inhibit > 90% of CPA 4 -hydroxylation catalyzed by uninduced rat liver microsomes under conditions where there was little inhibition of the corresponding reaction catalyzed by PBinduced rat liver microsomes, where CYP2B1 is the major P450 catalyst. However, difficulties encountered in DDEP solubility complicated in vivo administration of this compounds, leading us to drop DDEP from further consideration. ABT also showed preferential inhibition of uninduced liver microsomal CPA activation as compared with CYP2B-dependent CPA activation, although with a lower selectivity than DDEP. Substantial (albeit incomplete) inhibition of liver microsomal CPA 4 -hydroxylase activity could also be achieved when ABT was administered to rats in vivo. These results are consistent with the earlier finding that ABT treatment induces a profound reduction in liver and kidney P450 content in rats within 2 hours. This loss of P450 persists for at least 48 hours, with $80% of total hepatic P450 destroyed at a dose of ABT !10 mg /kg. 38 ABT is very safe and well tolerated when administered to rats chronically at 100 mg /kg /day over a 13-week period, with no overt clinical toxicity apparent, as indicated by the absence of changes in body weight, food consumption, and overall clinical appearance. 43 Although ABT and SKF -525A were both effective inhibitors of hepatic CPA activation, they did not increase the tumor growth delay effect of CPA in our cancer gene therapy rat model beyond that achieved with CPA treatment alone. Possible explanations include the following. First, the desired selectivity for inhibition of hepatic CPA activation without compromising tumor cell ± catalyzed CPA activation may not have been achieved. Second, although ABT and SKF -525A were inhibitory toward hepatic CPA activation, only partial inhibition was achieved at the doses used ( Fig  2 ) . Of note, although the C max of 4-OH -CPA was decreased $4-fold in response to ABT treatment, and the apparent t 1 / 2 was increased > 7-fold, as would be expected if the rate of liver P450 -dependent conversion of CPA to 4 -OH -CPA were greatly reduced, the net extent of CPA activation decreased by only $50% (cf., 50% decrease in AUC of 4 -OH -CPA in the ABT-treated rats; Table 1 ). Thus, CPA may have access to alternative routes of metabolism or elimination in rats where liver P450 metabolism is inhibited by ABT. Although this could lead to an increased exposure ( AUC ) of CYP2B1 -expressing tumor cells to CPA, which would be expected to enhance the antitumor effect, it is alternatively possible that this increased exposure might not be achieved due to cross -inhibition of the tumor-expressed CYP2B1 enzyme by ABT (cf., partial selectivity of ABT for CYP2C -catalyzed CPA activation; Fig 1B ) . Finally, the exposure of tumor cells to CPA may not increase even under conditions where the rate of hepatic CPA activation is selectively reduced, e.g., as a consequence of liver drug metabolism by alternative pathways, such as N -dechloroethylation. 28 Further, more detailed studies using inhibitors that are more potent and exhibit a more complete P450 form specificity are needed to clarify these issues.
ABT and SKF -525A did not reduce the systemic toxicities caused by CPA in the tumor-bearing rats, as judged by drug -induced body weight loss (Fig 6) and by monitoring CPA -induced hematuria (data not shown ). CPA -induced body weight loss in the inhibitor-treated rats was minimized by MMI administration, in agreement with our earlier finding that MMI reduces this host toxicity. 25 Toxicities associated with the P450 inhibitor ± CPA combinations may be one possible reason why the toxicities of CPA were not reduced under conditions where liver CPA activation was inhibited. Alternatively, the indicators of CPA toxicity monitored in this study (body weight loss and hematuria ) may primarily reflect total exposure to activated CPA metabolites ( i.e., AUC of 4-OH -CPA ), which was only modestly decreased by the P450 inhibitors, and may not be sufficiently sensitive to reveal more subtle changes in CPA's systemic toxicities, which may be associated with the more substantial decreases in 4 -OH -CPA C max values observed in the P450 inhibitor-treated rats. Further studies investigating other P450 form -selective inhibitors, as well as additional indicators of CPA -induced host toxicity such as bone marrow toxicity, may be useful in this regard.
In conclusion, P450 inhibitors of the appropriate P450 form specificity may be useful in reducing hepatic activation of CPA with little effect on the in situ activation of CPA within tumors transduced with a prodrug-activating CYP gene. Further preclinical studies will be required to test this possibility and to develop potential clinical applications for use in CPA -treated patients undergoing P450 gene therapy.
